Research Article

Dunye Guanxinning Improves Acute Myocardial Ischemia-Reperfusion Injury by Inhibiting Neutrophil Infiltration and Caspase-1 Activity

Q. G. Zhang, S. R. Wang, X. M. Chen, H. N. Guo, S. Ling, and J. W. Xu

Institute of Interdisciplinary Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Correspondence should be addressed to S. Ling; sarah_ling@126.com and J. W. Xu; jinwen.xu88@gmail.com

Received 27 July 2017; Revised 16 November 2017; Accepted 12 December 2017; Published 20 February 2018

Academic Editor: Vinod K. Mishra

Copyright © 2018 Q. G. Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acute myocardial infarction is the most serious manifestation of cardiovascular disease, and it is a life-threatening condition. Dunye Guanxinning (DG) is a protective traditional Chinese patent herbal medicine with high clinical efficacy and suitable for the treatment of myocardial infarction. However, the mechanism through which it is beneficial is unclear. In this study, we hypothesized that DG improves acute myocardial ischemia-reperfusion injury by inhibiting neutrophil infiltration and caspase-1 activity. We found that DG administration decreased infarct size and cardiomyocyte apoptosis and improved left ventricular ejection fraction, fractional shortening, end-systolic volume index, end-systolic diameter, and carotid arterial blood flow output in rats. DG administration also improved hemorheological parameters, myocardial damage biomarkers, and oxidative stress indexes. The findings showed that DG administration inhibited neutrophil infiltration and reduced the serum interleukin-1 beta (IL-1β) level and myocardial IL-1β maturation. Moreover, DG administration inhibited caspase-1 activity and activated adenosine monophosphate-activated protein kinase (AMPK) phosphorylation in rat hearts. These results suggested that DG administration inhibits inflammasome activity and IL-1β release through the AMPK pathway. Our findings support the clinical efficacy of DG and partially reveal its mechanism, which is beneficial for understanding the therapeutic effects of this protective traditional Chinese patent drug.

1. Introduction

Myocardial infarction is the leading cause of death worldwide, and it is associated with sudden death and is thus a serious threat to life and health. Myocardial ischemia-reperfusion (I/R) injury is the recovery of myocardial ischemia after a short period, resulting in further deterioration of myocardial function. The pathogenesis of myocardial infarction involves many factors. I/R injury first triggers neutrophil infiltration [1, 2] and subsequently initiates the generation of a large number of oxygen-free radicals [3, 4], primes the inflammatory response including inflammasome activation [5–7], induces apoptosis [8, 9], and so on. Myocardial I/R injury is also one of the important reasons for the failure of clinical thrombolytic therapy, coronary artery bypass grafting, and heart transplantation.

Dunye Guanxinning (DG) is a class B protective traditional Chinese patent drug in the Chinese Pharmacopoeia [10]. This drug is an extract obtained from the dried rhizomes of Dioscorea zingiberensis C. H. Wright, and it is used to treat hyperlipidemia, coronary heart disease, and angina and to improve symptoms of chest tightness, palpitation, dizziness, and insomnia [10]. The fresh rhizome contains various saponins such as Huangjiangsu A, zingiberensis new saponin, deltonin, dioscin, and gracillin (Table 1) [11]. Clinical investigations have found that DG can effectively lower the blood lipid level [12], decrease angina attack frequency, shorten angina onset time, and improve endothelial function and blood rheology [13, 14]. DG also effectively reduces serum homocysteine levels in patients with ischemic heart disease [15]. The combination of DG with other traditional patent drugs has been demonstrated to decrease the
incidence of angina pectoris, reinfarction, cardiac insufficiency, and platelet activation in patients with acute myocardial infarction [16]. DG effectively improves angina and myocardial infarction clinically; however, the mechanism by which it achieves this is unclear. Therefore, in this study, we used a myocardial I/R model to verify whether DG improves myocardial I/R injury by inhibiting neutrophil infiltration and inflammasome NLR family pyrin domain containing 3 (NLRP3) activity, providing a reliable basis for interpreting the mechanism of DG.

### 2. Materials and Methods

#### 2.1. Animal Ethics Statement and Animals.

The animals received care in compliance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health, and the animal experiments in this study were approved by the Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine (approval number SZY201510001).

Male Sprague–Dawley (SD) rats aged 7-8 weeks were purchased from Shanghai SIPPR-BK Lab Animal Co. Ltd. (Shanghai, China). Rats were housed in cages (three per cage) maintained at constant humidity (65±5%) and temperature (24°C±1°C) in a 12-hour light-dark cycle. Rats were allowed ad libitum access to tap water and food throughout the experimental protocols. Thirty-six male SD rats were randomly divided into the DG control, sham operation, I/R, and I/R + DG groups (12 per group). Rats in the I/R + DG group were given an equal volume of pure water. On the last day of treatment, rats were anesthetized using an intraperitoneal injection of sodium pentobarbital at a dose of 45 mg/kg, and significant elevation of the ST segment on the ECG was used as the index of successful ligation. After ST elevation detection, the blood vessel was expanded to allow reperfusion for 2 h. Sham-operated rats underwent similar procedures without ligation of the coronary arteries.

#### 2.2. Myocardial Ischemia-Reperfusion Model.

After rats were anesthetized using sodium pentobarbital, they were placed on an electric heating pad to maintain their body temperature at 37°C and were artificially ventilated using a volume-controlled RWD 407 rodent respirator (Shenzhen Reward Life Technology Co. Ltd., Shenzhen, China) with the respiration rate set at 70/min, tidal volume at 1.5 mL, and breathing time ratio at 1:1. Animal electrocardiogram (ECG) was monitored using a PowerLab 8-channel multifunctional physiological recorder (AD Instruments, Bella Vista, Australia). The left anterior descending coronary artery was ligated for 30 min, and the heart was excised and placed into a glass jar filled with cold saline to stop its beating. The heart was then transected at both ends, and the left ventricle was sent to the Institute for Pathological Science of the Shanghai Second Military Medical University for pathological examination.

#### 2.3. Left Ventricular Function Echocardiography.

Twenty-four hours after reperfusion, rats were anesthetized using 1.5% isoflurane. Their left ventricular function parameters, such as left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), end-systolic volume index, and end-systolic diameter (ESD), were determined using a Vevo 770 High-Resolution Imaging System (VisualSonics Inc., Toronto, Ontario, Canada).

#### 2.4. Western Blot Assay.

The left ventricular tissue was lysed in ice-cold radioimmunoprecipitation assay buffer (50 mmol/L Tris/HCl, pH 8.0; 150 mmol/L NaCl; 2 mmol/L sodium orthovanadate; 1% Nonidet-P40, 1% sodium deoxycholate; 0.1% sodium dodecyl sulfate (SDS); 0.1 mmol/L dithiothreitol; 0.05 mmol/L phenylmethylsulfonyl fluoride; 0.002 mg/mL aprotinin; and 0.002 mg/mL leupeptin). Lysates were precleared through centrifugation at 12000 × g for 10 min at 4°C. Aliquots of the cell lysate (50 or 100 μg of each sample) were resolved on SDS-polyacrylamide gel electrophoresis and were transferred to nitrocellulose membranes. The membranes were blocked in 5% skimmed milk overnight at 4°C. The membranes were incubated with primary antibodies for 2 h and then incubated with an HRP-conjugated secondary antibody at room temperature for 1 h. The bands were visualized using an ECL Immobilon Western Chemiluminescent HRP substrate (Millipore, Billerica, MA, USA). Quantitative analysis of band density was performed using Quantity One software from Bio-Rad (Hercules, CA, USA). Western blot experiments were performed in triplicate [17].

#### 2.5. Immunohistochemical Staining.

Formalin-fixed and paraffin-embedded tissue section blocks were cut in 6 μm sections, followed by immunohistochemical staining with primary antibodies of anti-cleaved caspase-3 (GB13009  Whan Servicebio Technology Co. Ltd., Wuhan, China), anti-CD68 (GB13067-1, Servicebio), anti-MPO (GB13224, Servicebio), or anti-CD15 (GTX37536, GenTex, Irvine, USA) and goat anti-mouse or anti-rabbit IgG secondary antibodies. The EnVision (Peroxidase/DAB, Rabbit/Mouse) detection system was used to evaluate the immunohistochemical staining. TUNEL staining was performed using the In Situ Cell Death Detection Kit (11684817910, Roche, China).
Mannheim, Germany). The intensity of the immunohistochemical staining was analyzed using the ImageJ analysis system (NIH, Maryland, USA).

2.5.1. ELISA Assay. The ELISA assay was performed using the rat IL-1β ELISA kit (ab100768, Abcam, Cambridge, UK) or rat interleukin-1β, rat interleukin-6, and rat interleukin-18 ELISA assay kits (H002, H007, and H015, Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturers’ instructions.

2.6. Determination of Hemodynamic Parameters. After 30 min of myocardial ischemia and 2 h after reperfusion, rats were anesthetized using an intraperitoneal injection of 1% sodium pentobarbital (3 mL·kg\(^{-1}\)). A total of 5 mL of blood was collected through the aorta ventralis and was rapidly transferred to a tube containing the anticoagulant heparin. Subsequently, blood rheology was determined using an MEN-C100A automatic blood rheological dynamic analyzer (Shandong Meiyilin Electronic Instrument Co. Ltd., Jinan, China).

2.7. Detection of Hemorheological Parameters. Two hours after reperfusion, rats were anesthetized using an intraperitoneal injection of 1% sodium pentobarbital (3 mL·kg\(^{-1}\)). A total of 5 mL of blood was collected through the aorta ventralis and was rapidly transferred to a tube containing the anticoagulant heparin. Subsequently, blood rheology was detected using an MEN-C100A automatic blood rheological dynamic analyzer (Shandong Meiyilin Electronic Instrument Co. Ltd., Jinan, China).

2.8. Preparation of Myocardial Tissue Supernatants and Myocardial Enzyme Activity Assay. Cardiac tissue samples in a tissue weight/normal saline ratio of 1:9 were placed in a liquid-nitrogen-cooled JXFSTPRP-192 automatic fast sample mill (Shanghai Jingxin Industrial Development Co. Ltd., Shanghai, China) and were ground (frequency of 75 for 50 s) twice. The tissue homogenates were removed and sonicated five times every 5 s at 10 s intervals in an ice bath on a JY92-2D ultrasonic homogenizer (NingBo Scientz Biotechnology Co. Ltd., Zhejiang, China) and were ground (frequency of 75 for a liquid-nitrogen-cooled JXFSTPRP-192 automatic fast sample mill (Shanghai Jingxin Industrial Development Co. Ltd., Shanghai, China) and were ground (frequency of 75 for 50 s) twice. The tissue homogenates were removed and sonicated five times every 5 s at 10 s intervals in an ice bath on a JY92-2D ultrasonic homogenizer (NingBo Scientz Biotechnology Co. Ltd., Zhejiang, China). The samples were subsequently centrifuged at 2500 rpm for 10 min at 4°C. The separated tissue supernatants were extracted, and their protein concentrations were measured using Coomassie brilliant blue. The supernatants obtained after centrifugation of the myocardial tissue were diluted 10-fold, packed, and placed in a −80°C freezer.

Using procedures specified by the manufacturer, we determined LDH activity, CK-MB activity, catalase activity, GSH-PX activity, and GSH content using the appropriate test kits. The ideal sample concentration and measurement condition were identified according to a response curve.

2.9. Statistical Analysis. Data were analyzed using SPSS (SPSS Inc., Northampton, USA), and the means and standard deviations of the data were calculated. Pairwise comparisons were made using the Mann–Whitney U test, and comparisons were made between treatment groups by using analysis of variance and post hoc tests. \(P < 0.05\) was considered statistically significant.

3. Results

As shown in Figure 1, TTC staining revealed that the myocardial infarct size was significantly higher in the myocardial I/R group, reaching 24.51% ± 8.91%, than in the sham operation group (each \(n = 6 \) or 7, \(P < 0.01\)). By contrast, the prophylactic administration of DG for 2 weeks resulted in a significantly smaller myocardial infarction area of 3.52% ± 1.48% (each \(n = 6 \) or 7, \(P < 0.01\)). To determine the type of tissue death, tissue staining was performed using the cleaved caspase-3 antibody. The results showed that the number of cleaved caspase-3 stained positive cells in the myocardial infarction area of the I/R group was significantly higher (76.72% ± 11.89%) than that of the sham operation group. However, the results of section staining revealed that the apoptotic staining density of TUNEL was 18.74 ± 1.43-fold greater than that in the sham operation group (1.00 ± 0.46, each \(n = 3\), \(P < 0.01\); Figures 2(a) and 2(b)). The apoptotic staining optical density in the DG administration group was reduced by 6.68 ± 0.21-fold and was significantly lower than that in the I/R group (\(n = 3\), \(P < 0.01\); Figures 2(c) and 2(d)). Western blotting was used to examine protein expression. The expression of cleaved caspase-3 in the myocardial I/R group was a factor of 2.47 ± 0.85 higher than that in the sham operation group. By contrast, the expression of cleaved caspase-3 in the DG administration group was a factor of 1.36 ± 0.28 lower than that in the I/R group (each \(n = 3\), \(P < 0.05\); Figure 2(e)). These results demonstrated that DG reduces myocardial damage and apoptosis caused by I/R injury.

To analyze the effect of DG administration on cardiac function, we used the Vevo Visual 770 Sonics small animal imaging system to evaluate cardiac function on 24 ± 2 h after I/R injury. The ultrasonic reflected wave of the left ventricular wall in the I/R group was flat, suggesting that the left ventricular wall was damaged and the I/R injury model was successfully established. By contrast, the reflected wave had a wave pattern in the I/R + DG group (Figure 3(a)). In the I/R group, the LVEF and fractional shortening decreased to 64.99% ± 6.66% and 36.52% ± 5.29%, respectively (\(n = 3\), \(P < 0.05\); Figures 3(b) and 3(c)), and the end-systolic volume index and ESD of the left ventricle increased to 69.49 ± 5.29% and 47.73% ± 4.72%, respectively, and the end-systolic volume index and ESD were restored to 48.86 ± 12.69 μL and 3.42 ± 0.35 mm, respectively (\(n = 3\), \(P < 0.05\); Figures 3(d) and 3(e)). Blood flow in internal carotid arteries was also determined. The results showed that carotid arterial blood flow decreased from 3.36 ± 1.16 mL/min in the sham operation group to 1.71 ± 0.61 mL/min in the I/R group. However, DG administration restored the blood flow to 3.03 ± 1.52 mL/min (\(n = 10\), \(P < 0.05\); Figure 3(f)). These results demonstrated that DG improves the recovery of cardiac function after I/R injury.
Subsequently, myocardial CK-MB and LDH activities in the rat serum were measured. The results revealed that CK-MB activity in the I/R group was significantly higher at 1.56 ± 0.72 U/mL compared with that in the sham operation group (0.83 ± 0.28 U/mL, n = 10, P < 0.01; Table 2). By contrast, the serum CK-MB activity in the I/R + DG group was significantly lower at 0.92 ± 0.29 U/mL than that in the I/R group (n = 10, P < 0.01; Table 2). Serum LDH activity exhibited a trend similar to that of CK-MB activity. Serum LDH activity in the I/R group was significantly higher at 5827.39 ± 1871.24 U/L compared with that in the sham operation group (3365.37 ± 1357.24 U/L). By contrast, serum LDH activity in the DG administration group was lower at 3365.37 ± 1165.87 U/L (each n = 10, P < 0.01; Table 2). These results suggested that DG administration improves hemorheological parameters.

A previous study demonstrated that neutrophil accumulation occurs in response to acute ischemic myocardial injury [21]. Regarding the temporal dynamics of neutrophils, the number of neutrophils was found to immediately increase to a peak value within 3 days [22]. Therefore, to determine the extent of neutrophil infiltration in the myocardium, we used the anti-CD15 antibody to detect the expression of CD15, which mediates the phagocytosis and chemotaxis of neutrophils [23], in section staining and Western blotting. The results of section staining showed that neutrophils accumulated rapidly at 2 h after I/R injury. Moreover, the optical density in the I/R injury group (7882.65 ± 1703.96) was much higher than that in the sham operation group (499.50 ± 272.88, each n = 3, P < 0.01; Figure 4(a)).

Because hemorheological parameters have been found to be associated with I/R [18–20], we also measured whole blood viscosity (WBV), erythrocyte sedimentation rate (ESR), and hematocrit (Htc). WBV at shear rates of 200 s⁻¹, 50 s⁻¹, and 10 s⁻¹ was discovered to increase significantly from 3.52 ± 0.29 mPa/s/200 s⁻¹, 3.88 ± 0.35 mPa/s/50 s⁻¹, and 4.71 ± 0.48 mPa·s/10 s⁻¹ in the sham operation group to 4.23 ± 0.42 mPa·s/200 s⁻¹, 4.75 ± 0.44 mPa·s/50 s⁻¹, and 5.68 ± 2.56 mPa·s/10 s⁻¹ in the I/R group, respectively (each n = 6, P < 0.01; Table 3). DG administration decreased the WBV at shear rates of 200 s⁻¹, 50 s⁻¹, and 10 s⁻¹ to 3.33 ± 0.14 mPa·s/200 s⁻¹, 3.75 ± 0.15 mPa·s/50 s⁻¹, and 4.50 ± 0.28 mPa·s/10 s⁻¹, respectively (each n = 6, P < 0.01; Table 3). ESR decreased from 0.98 ± 0.15 mm/h in the sham operation group to 0.58 ± 0.06 mm/h in the I/R group. By contrast, in the DG administration group, ESR increased to 1.10 ± 0.24 mm/h (each n = 6, P < 0.01; Table 3). We also found that Htc did not change (Table 3). These results suggested that DG administration improves hemorheological parameters.
that MPO expression in the I/R group was 8.67 ± 0.46-fold higher than that in the sham group (1.00 ± 0.07-fold) and that DG administration reduced the expression of MPO to 2.76 ± 0.29-fold (n = 3, P < 0.01; Figure 4(c)). However, labeling of macrophages with the CD68 antibody revealed a limited number of macrophage infiltrates in the injured myocardium. Compared with the 0.30 ± 0.13 cells per microscope field (400x) in the sham group, there were only 7.13 ± 0.80 cells per microscope field (400x) in the macrophage infiltrates. However, a difference was observed between the sham and I/R groups, and DG could also reduce the infiltration of macrophages (2.43 ± 0.49 cells per microscope field (400x); n = 3, P < 0.01; Figure 4(d)). These results suggest that neutrophils were the major inflammatory cells after 2 h of I/R.

Neutrophil invasion and activation may potentiate the inflammatory response. Therefore, we examined changes in
the content of damaged myocardial interleukin-1β (IL-1β). At 2 h after I/R injury, the IL-1β level in the damaged myocardial homogenate of rats was 1948.46 ± 237.04 pg/mg in the I/R group, compared with 1697.97 ± 225.71 pg/mg in the sham operation group. By contrast, this effect was reversed in the I/R + DG group, which had IL-1β concentration of 1509.44 ± 302.77 pg/mg (each n = 8, P < 0.01; Figure 5(a)). This difference in the serum IL-1β concentration may be catalyzed by inflammasomes. Thus, we examined the changes in IL-1β maturation in the myocardium. Although we found no changes in pro-IL-1β expression in the I/R group or the I/R + DG group (Figures 5(b) and 5(c)), IL-1β expression in the myocardium was significantly a factor of 2.29 ± 0.54 higher in the I/R group. By contrast,
in the I/R + DG group, the expression of IL-1β protein in the myocardium was significantly a factor of 1.30 ± 0.38 lower (each \( n = 4, P < 0.01 \); Figures 5(b) and 5(d)). We also measured serum levels of IL-1β, IL-6, and IL-18. Serum levels of IL-1β, IL-6, and IL-18 in the I/R myocardial injury group (47.06 ± 9.77 pg/mL, 86.59 ± 30.52 pg/mL, and 84.06 ± 19.89 pg/mL, resp.) were significantly higher than those in the sham group (4.36 ± 1.99 pg/mL, 11.32 ± 4.85 pg/mL, and 3.18 ± 1.25 pg/mL, resp.), and DG administration reduced their serum levels (18.59 ± 3.53 pg/mL, 36.08 ± 16.30 pg/mL, and 25.14 ± 13.88 pg/mL, resp.) (each \( n = 8, P < 0.01 \); Figures 5(e)–5(g)). These results demonstrated that DG inhibits neutrophil infiltration and IL-1β maturation in the myocardium.

Furthermore, to explore the mechanisms through which DG administration reduces IL-1β release caused by acute I/R, we examined caspase-1 activity. I/R injury promoted an approximately threefold increase in cleaved caspase-1, and the cleaved caspase-1/GAPDH ratio was 0.29 ± 0.06 in the sham operation group compared with 0.75 ± 0.25 in the I/R group. DG administration inhibited caspase-1 activity and resulted in a ratio of 0.39 ± 0.16 (each \( n = 4, P < 0.01 \); Figures 6(a) and 6(b)). We also found that I/R injury activated the phosphorylation of AMPK, consistent with a previous report [25]. The phospho-AMPK ratio was 0.47 ± 0.09 in the sham operation group but 0.68 ± 0.01 in the I/R group (each \( n = 4, P < 0.01 \); Figures 6(c) and 6(d)). DG administration further improved the phospho-AMPK ratio to 1.00 ± 0.12 (each \( n = 4, P < 0.01 \); Figures 6(c) and 6(d)).

4. Discussion

Our results showed that cardiac function was significantly impaired in the I/R group compared with that in the sham operation group. By contrast, the LVEF and LVFS were significantly improved in the I/R + DG group. Furthermore, I/R injury caused a significant reduction in arterial blood flow; however, DG administration resulted in significantly increased carotid arterial blood flow output per minute. In addition, DG administration reduced the myocardial I/R injury infarct area, myocardial apoptosis, and oxidative stress. These findings suggested the high efficacy of DG administration against I/R injury.

Earlier studies have demonstrated that neutrophils participate in the early stages of myocardial I/R injury [21, 26–28]. Our findings showed that DG administration effectively inhibited neutrophil infiltration in the acute myocardial infarction area. Recent studies have demonstrated that myocardial I/R injury causes increased plasma nucleosomes, abundant neutrophil infiltration, and neutrophil extracellular trap formation (NETosis) at the injury site [29]. Moreover, NETosis-mediated microthrombosis was shown to contribute to myocardial "no-reflow" [30]. NETosis may cause chromatin release and extracellular histone accumulation, which induces myocardial cytotoxicity and death and sterile inflammation in the infarcted myocardium [29, 31]. In addition, extracellular histones cause sterile inflammation by activating the NLRP3 inflammasome [32]. Conversely, NLRP3 regulates neutrophil function and contributes to I/R injury [33]. Therefore, DG administration may reduce NETosis, sterile inflammation, myocyte death, and microthrombosis by blocking neutrophil infiltration. Moreover, in the present study, DG administration resulted in increased GSH-Px activity. Early studies have reported that the antioxidant GSH-Px is closely associated with cardiac I/R injury [34, 35]. Early neutrophil infiltration caused by I/R injury induces oxidative stress [36, 37]. This evidence supports that NADPH oxidase and myeloperoxidase are involved in NETosis [38, 39]. Other studies have confirmed that the inhibition of autophagy or NADPH oxidase prevents intracellular chromatin decondensation, which is essential for NETosis [40].

A series of proinflammatory and anti-inflammatory cytokines are well-known to play an important role in myocardial

| Group          | Serum CK-MB (U/mL) | Serum LDH (U/L) | Cardiac GSH-Px (U/mg protein) | Cardiac GSH (μmol/g protein) |
|----------------|--------------------|-----------------|-------------------------------|-----------------------------|
| Sham           | 0.83 ± 0.72        | 3365.37 ± 1357.24 | 320.27 ± 76.48               | 12.15 ± 5.66                |
| I/R            | 1.56 ± 0.28**      | 5827.39 ± 1871.24**| 241.07 ± 76.66**             | 6.84 ± 1.53**               |
| DG-treated     | 0.92 ± 0.29##      | 4112.27 ± 1165.87##| 327.53 ± 62.91##             | 14.40 ± 10.32##             |

Data are expressed as mean ± SD. \( n = 10 \). **P < 0.01 versus sham operation group; ##P < 0.05 and ###P < 0.01 versus I/R group. CK-MB: myocardial creatine kinase isoenzyme; GSH: glutathione; GSH-Px: glutathione peroxidase; I/R: ischemia-reperfusion; LDH: lactate dehydrogenase.

| Group          | WBV (mPa-s) 200 s⁻¹ | WBV (mPa-s) 50 s⁻¹ | 10 s⁻¹ | ESR (mm/h) | Htc (%) |
|----------------|---------------------|-------------------|--------|------------|---------|
| DG             | 3.55 ± 0.18         | 3.93 ± 0.13       | 4.70 ± 0.15 | 1.05 ± 0.04 | 50.70 ± 0.69 |
| Sham           | 3.52 ± 0.29         | 3.88 ± 0.35       | 4.71 ± 0.48 | 0.98 ± 0.15 | 50.86 ± 2.89 |
| I/R            | 4.23 ± 0.42**       | 4.75 ± 0.44**     | 5.68 ± 2.56** | 0.58 ± 0.06** | 48.68 ± 2.34 |
| DG-treated     | 3.33 ± 0.14##       | 3.75 ± 0.15##     | 4.50 ± 0.28## | 1.10 ± 0.24## | 50.48 ± 2.21 |

Data are expressed as mean ± SD. \( n = 6 \). **P < 0.01 versus sham operation group; ##P < 0.01 versus I/R group. ESR: erythrocyte sedimentation rate; Htc: hematocrit; I/R: ischemia-reperfusion; WBV: whole blood viscosity.
I/R injury. IL-1β is one of the most effective early proinflammatory mediators. Previous studies have reported that the ischemic heart exhibited enhanced inflammasome activation, as demonstrated by increased caspase-1 activity and increased IL-1β production [41, 42]. It has also been reported that the ischemic heart exhibited enhanced inflammasome NLRP3 expression and caspase-1 activity [43, 44]. Many studies have discovered that IL-1β is a critical early inflammatory mediator in myocardial I/R injury, and antagonism of IL-1β may have cardioprotective effects [45, 46]. Our results showed that DG administration resulted in significantly decreased myocardial caspase-1 activity and IL-1β maturation after myocardial I/R injury. Although studies have revealed that neutrophils and macrophages collaborate to promote IL-1β maturation, and cause IL-1β-driven and I/R-induced inflammation [47], our results indicated that only a low level of macrophage infiltration occurred in each visual field in the area of myocardial I/R injury at 2 h compared with the sham operation group. Conversely, neutrophil infiltration was substantial. Because neutrophils express key components of inflammasomes and release IL-1β and IL-18 proteins [48], it is suggested that DG may be mainly targeted to neutrophil inflammasomes.

Moreover, our results revealed that DG administration activated the phosphorylation of myocardial AMPK during I/R injury. AMPK is a metabolic sensor that coordinates...
intracellular ATP synthesis and decomposition; thus, AMPK maintains cellular energy homeostasis through the phosphorylation of multiple proteins involved in metabolic pathways [49]. However, the protein abundance and activity of serine/threonine kinase 11, an upstream signaling molecule for AMPK, have been found to be similar in both aerobic and ischemic hearts [25]. Previous studies of our and other groups have demonstrated that ingredients in Chinese medical herbs, such as 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside, bavachalcone, diosgenin, and pterostilbene,
stimulated the AMPK activity and anti-inflammatory effects [17, 50–55]. To date, some studies have demonstrated that the activation of AMPK inhibits NLRP3 expression, caspase-1 activity, and IL-1β secretion [56–58].

Hemorheological parameters are closely related to hemodynamics, and an increase in low shear blood viscosity is associated with an increased risk of thrombosis [59]. Furthermore, increased red blood cell aggregation is a reflection of inflammation [60, 61]. Moreover, oxidative stress is one of the major factors promoting changes in blood and viscosity [61, 62]. Myocardial I/R injury also causes changes in hemorheological parameters [18–20]. Our results suggested that DG administration improves hemorheology by ameliorating oxidative stress and the inflammatory response.

Our findings revealed that DG administration improved cardiac function, reduced the infarct area, and inhibited cardiomyocyte apoptosis at least partly by inhibiting neutrophil infiltration, activating AMPK phosphorylation, and inhibiting caspase-1 activity and IL-1β release during myocardial I/R injury. The findings support the clinical efficacy of DG and partially reveal its mechanism, which is beneficial for understanding the therapeutic effects of the protective traditional Chinese patent drug.

Abbreviations

AMPK: Adenosine monophosphate-activated protein kinase
CK-MB: Creatine kinase isoenzyme MB
DG: Dunye Guanxinning
ECG: Electrocardiogram
ESD: End-systolic diameter
ESR: Erythrocyte sedimentation rate
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase
GSH-Px: Glutathione peroxidase
HRP: Horseradish peroxidase
Hct: Hematocrit
IL-1β: Interleukin-1 beta
LDH: Lactate dehydrogenase
LVEF: Left ventricular ejection fraction
LVFS: Left ventricular fractional shortening
NLRP3: NLR family pyrin domain containing 3
SD rat: Sprague-Dawley rat
TTC: 2,3,5-Triphenyltetrazolium chloride
WBV: Whole blood viscosity

Conflicts of Interest

The authors confirm that there are no conflicts of interest.

Acknowledgments

This study was supported by grants from the Shanghai 085 Project of Higher Education Connotation Construction (085ZY1202).
References

[1] Z. V. Schofield, T. M. Woodruff, R. Halai, M. C.-L. Wu, and M. A. Cooper, "Neutrophils—a key component of ischemia-reperfusion injury," *Shock*, vol. 40, no. 6, pp. 463–470, 2013.

[2] P. P. Rainer, S. Hao, D. Vanhoutte et al., "Cardiomyocyte-specific transforming growth factor β suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction," *Circulation Research*, vol. 114, no. 8, pp. 1246–1257, 2014.

[3] A. Sirker, C. E. Murdoch, A. Protti et al., "Cell-specific effects of Nox2 on the acute and chronic response to myocardial infarction," *Journal of Molecular and Cellular Cardiology*, vol. 98, pp. 11–17, 2016.

[4] C. Doerrries, K. Grote, D. Hilfiker-Kleiner et al., "Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction," *Circulation Research*, vol. 100, no. 6, pp. 894–903, 2007.

[5] N. G. Frangogiannis, "The inflammatory response in myocardial injury, repair, and remodelling," *Nature Reviews Cardiology*, vol. 11, no. 5, pp. 255–265, 2014.

[6] M. Takahashi, "Role of the inflammusome in myocardial infarction," *Trends in Cardiovascular Medicine*, vol. 21, no. 2, pp. 37–41, 2011.

[7] M. Kagawuchi, M. Takahashi, T. Hata et al., "Inflammusome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury," *Circulation*, vol. 123, no. 6, pp. 594–604, 2011.

[8] J. Xia, F. Xu, Y. Qu, D. Song, H. Shen, and X. Liu, "Atrovastatin post-conditioning attenuates myocardial ischemia reperfusion injury via inhibiting endoplasmic reticulum stress–related apoptosis," *Shock*, vol. 42, no. 4, pp. 365–371, 2014.

[9] S. Toldo, D. G. Breckenridge, E. Mezaroma et al., "Inhibition of apoptosis signal–regulating kinase 1 reduces myocardial ischemia–reperfusion injury in the mouse," *Journal of the American Heart Association*, vol. 1, no. 5, article e002360, 2012.

[10] The People’s Republic of China Ministry of Health Drug Standards (Chinese medicine into prescription), *Dunye Guanxinning Pian (WS3-B-3282-98)*, vol. 1, p. 191, Chinese Pharmacopoeia Commission, China, 1989.

[11] Z. X. Xin, L. J. Ru, S. Qi, X. R. Ming, and S. W. Ji, "Simultaneous content determination of five saponins in the rhizome of *Dioscorea zingiberensis* C.H.Wright by HPLC-ELSD*, *Chinese Journal of Pharmaceutical Analysis*, vol. 33, no. 7, pp. 1235–1238, 2013.

[12] Z. Nan, Z. Jie, L. Z. Li, and G. H. Tao, "Clinical study of Dunye Guanxinning tablets in the treatment of hyperlipidemia," *Chinese Journal of Integrated Medicine on Cardio/Cerebrovascular Disease*, vol. 7, no. 3, pp. 255–256, 2009.

[13] H. Lu, N. Zhang, J. Zhang, and H. Ge, "Clinical study on "Dunye Guanxinning Tablet" in treating coronary angiography pectoris of Qi-Blood stagnation," *Shanghai Journal of Traditional Chinese Medicine*, vol. 42, no. 11, pp. 30–32, 2008.

[14] L. Juan, N. Y. Yuan, Z. Y. Ying, and H. G. Hong, "45 cases report of Dunye Guanxinning tablets in the treatment of coronary heart disease and angiography pectoris with Qi-stagnation/blood-stasis type," *Traditional Chinese Medicinal Research*, vol. 29, no. 6, pp. 9–11, 2016.

[15] S. W. Qing, L. Gang, and Z. M. Qi, "The clinical effect of Dunye Guanxinning on coronary heart disease and serum homocysteine," *Chinese Journal of Clinical Rational Drug Use*, vol. 9, no. 4, pp. 26–27, 2016.

[16] L. A. Zhen, Z. X. Ying, D. Tao, W. H. Qing, G. J. Yan, and W. Liang, "Therapeutic effect of Danhong injection combined with Dunye Guanxinning tablet on acute myocardial infarction and its effect on platelet activation biomarkers," *Modern Journal of Integrated Traditional Chinese and Western Medicine*, vol. 25, no. 6, pp. 615–617, 2016.

[17] W. Gan, Y. Dang, X. Han et al., "ERK5/HDAC5-mediated, resveratrol-, and pterostilbene-induced expression of MnSOD in human endothelial cells," *Molecular Nutrition & Food Research*, vol. 60, no. 2, pp. 266–277, 2016.

[18] N. Nemeth, I. Furka, and I. Mikó, "Hemorheological changes in ischemia-reperfusion: an overview on our experimental surgical data," *Clinical Hemorheology and Microcirculation*, vol. 57, no. 3, pp. 215–225, 2014.

[19] D. Kuke, L. Donghua, S. Xiaoyan, and Z. Yanjun, "Alteration of blood hemorheologic properties during cerebral ischemia and reperfusion in rats," *Journal of Biomechanics*, vol. 34, no. 2, pp. 171–175, 2001.

[20] E. Cecchi, A. A. Liotta, A. M. Gori et al., "Comparison of hemorheological variables in ST-elevation myocardial infarction versus those in non-ST-elevation myocardial infarction or unstable angina pectoris," *The American Journal of Cardiology*, vol. 102, no. 2, pp. 125–128, 2008.

[21] J. L. Romson, B. G. Hook, S. L. Kunkel, G. D. Abrams, M. A. Schork, and B. R. Lucchesi, "Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog," *Circulation*, vol. 67, no. 5, pp. 1016–1023, 1983.

[22] X. Yan, A. Anzai, Y. Katsumata et al., "Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction," *Journal of Molecular and Cellular Cardiology*, vol. 62, pp. 24–35, 2013.

[23] M. A. Kerr and S. Craig Stocks, "The role of CD15-(Le^-)-related carbohydrates in neutrophil adhesion," *The Histochemical Journal*, vol. 24, no. 11, pp. 811–826, 1992.

[24] M. O. Breckwoldt, J. W. Chen, L. Stangenberg et al., "Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 47, pp. 18584–18589, 2008.

[25] J. Y. Altarejos, M. Taniguchi, A. S. Clanchan, and G. D. Lopaschuk, "Myocardial ischemia differentially regulates LKB1 and an alternate 5′-AMP-activated protein kinase kinase," *The Journal of Biological Chemistry*, vol. 280, no. 1, pp. 183–190, 2005.

[26] P. J. Simpson, J. C. Fantone, J. K. Mickelson, K. P. Gallagher, and B. R. Lucchesi, "Identification of a time window for therapy to reduce experimental canine myocardial injury: suppression of neutrophil activation during 72 hours of reperfusion," *Circulation Research*, vol. 63, no. 6, pp. 1070–1079, 1988.

[27] M. R. Litt, R. W. Jeremy, H. F. Weisman, J. A. Winkelstein, and L. C. Becker, "Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury," *Circulation*, vol. 80, no. 6, pp. 1816–1827, 1989.

[28] F. Carbone, A. Nencioni, F. Mach, N. Vuilleumier, and F. Montecucco, "Pathophysiological role of neutrophils in acute myocardial infarction," *Thrombosis and Haemostasis*, vol. 110, no. 3, pp. 501–514, 2013.
mediators of inflammation

[29] A. S. Savchenko, J. I. Borisoff, K. Martinod et al., "VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice," Blood, vol. 123, no. 1, pp. 141–148, 2014.

[30] L. Ge, X. Zhou, W. J. Ji et al., "Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy," American Journal of Physiology-Heart and Circulatory Physiology, vol. 308, no. 5, pp. H500–H509, 2015.

[31] B. Vogel, H. Shinagawa, U. Hofmann, G. Ertl, and S. Frantz, "Acute DNase1 treatment improves left ventricular remodeling after myocardial infarction by disruption of free chromatin," Basic Research in Cardiology, vol. 110, no. 2, p. 15, 2015.

[32] H. Huang, H. W. Chen, J. Evanovich et al., "Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury," Journal of Immunology, vol. 191, no. 5, pp. 2665–2679, 2013.

[33] Y. Inoue, K. Shirasuna, H. Kimura et al., "NLRP3 regulates neutrophil functions and contributes to hepatic ischemia–reperfusion injury independently of inflammasomes," Journal of Immunology, vol. 192, no. 9, pp. 4342–4351, 2014.

[34] T. Yoshiida, N. Maulik, R. M. Engelman et al., "Glutathione peroxidase knockout mice are susceptible to myocardial ischemia reperfusion injury," Circulation, vol. 96, no. 9, article II-216-20, 1997Supplement, 1997.

[35] T. Yoshiida, M. Watanabe, D. T. Engelman et al., "Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia reperfusion injury," Journal of Molecular and Cellular Cardiology, vol. 28, no. 8, pp. 1759–1766, 1996.

[36] F. Montecucco, I. Bauer, V. Braunersreuther et al., "Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction," Antioxidants & Redox Signaling, vol. 18, no. 6, pp. 630–641, 2013.

[37] V. Braunersreuther, F. Montecucco, M. Ashri et al., "Role of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in myocardial ischemia/reperfusion injury," Journal of Molecular and Cellular Cardiology, vol. 64, pp. 99–107, 2013.

[38] T. Kirchner, S. Möller, M. Klinger, W. Solbach, T. Laskay, and K. Kirchner, S. Möller, M. Klinger, W. Solbach, T. Laskay, and K. Author, "The impact of various reactive oxygen species on the formation of neutrophil extracellular traps," Mediators of Inflammation, vol. 2012, Article ID 849136, 10 pages, 2012.

[39] A. B. Al-Khafaji, S. Tohme, H. O. Yazdani, D. Miller, H. Huang, and A. Tsung, "Superoxide induces neutrophil extracellular trap formation in a TLR-4 and NOX-dependent mechanism," Molecular Medicine, vol. 22, no. 1, p. 1, 2016.

[40] Q. Remijesen, T. Vanden Bergh, E. Wirawan et al., "Neutrophil extracellular trap cell death requires both autophagy and superoxide generation," Cell Research, vol. 21, no. 2, pp. 290–304, 2011.

[41] F. Martinon, K. Burns, and J. Tschopp, "The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1β," Molecular Cell, vol. 10, no. 2, pp. 417–426, 2002.

[42] E. Mezzaroma, S. Toldo, D. Farkas et al., "The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 49, pp. 19725–19730, 2011.

[43] Y. Liu, K. Lian, L. Zhang et al., "TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury," Basic Research in Cardiology, vol. 109, no. 5, p. 415, 2014.

[44] S. Toldo, C. Marchetti, A. G. Mauro et al., "Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia–reperfusion in the mouse," International Journal of Cardiology, vol. 209, pp. 215–220, 2016.

[45] B. J. Pomerantz, L. L. Reznikov, A. H. Harken, and C. A. Dinarello, "Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2871–2876, 2001.

[46] K. Suzuki, B. Murtuza, R. T. Smolenski et al., "Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis," Circulation, vol. 104, Supplement 1, pp. I-308–I-313, 2001.

[47] A. Sadatomo, Y. Inoue, H. Ito et al., "Interaction of neutrophils with macrophages promotes IL-1β maturation and contributes to hepatic ischemia–reperfusion injury," Journal of Immunology, vol. 199, no. 9, pp. 3306–3315, 2017.

[48] M. Bakele, M. Joos, S. Burdi et al., "Localization and functionality of the inflammasome in neutrophils," The Journal of Biological Chemistry, vol. 289, no. 8, pp. 5320–5329, 2014.

[49] D. Qi and L. H. Young, "AMPK: energy sensor and survival mechanism in the ischemic heart," Trends in Endocrinology & Metabolism, vol. 26, no. 8, pp. 422–429, 2015.

[50] S. Ling, J. Duan, R. Ni, and J.-W. Wu, "2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside promotes expression of the longevity gene klotho," Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3128235, 11 pages, 2016.

[51] S. Y. Park, M. L. Jin, Z. Wang, G. Park, and Y. W. Choi, "2,3,4′-5-tetrahydroxystilbene-2-O-β-D-glucoside exerts anti-inflammatory effects on lipopolysaccharide-stimulated microglia by inhibiting NF-κB and activating AMPK/Nrf2 pathways," Food and Chemical Toxicology, vol. 97, pp. 159–167, 2016.

[52] S. Ling, R. Z. Ni, Y. Yuan et al., "Natural compound bavachalcone promotes the differentiation of endothelial progenitor cells and neovascularization through the RORα-erythropoietin-AMPK axis," Oncotarget, vol. 8, no. 49, pp. 86188–86205, 2017.

[53] Y. Chen, X. Xu, Y. Zhang et al., "Diosgenin regulates adipokine expression in perivascular adipose tissue and ameliorates endothelial dysfunction via regulation of AMPK," The Journal of Steroid Biochemistry & Molecular Biology, vol. 155, Part A, pp. 155–165, 2016.

[54] S. Hiraï, T. Uemura, N. Mizoguchi et al., "Diosgenin attenuates inflammatory changes in the interaction between adipocytes and macrophages," Molecular Nutrition & Food Research, vol. 54, no. 6, pp. 797–804, 2010.

[55] J. Liu, C. Fan, L. Yu et al., "Pterostilbene exerts an anti-inflammatory effect via regulating endoplasmic reticulum stress in endothelial cells," Cytokine, vol. 77, pp. 88–97, 2016.

[56] Y. Wang, B. Viollet, R. Terkeltaub, and R. Liu-Bryan, "AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages," Annals of the Rheumatic Diseases, vol. 75, no. 1, pp. 286–294, 2016.

[57] O. M. Finucane, C. L. Lyons, A. M. Murphy et al., "Monounsaturated fatty acid–enriched high-fat diets impede adipose NLRP3 inflammasome–mediated IL-1β secretion and insulin resistance in obese mice," Basic Research in Cardiology, vol. 109, no. 5, p. 415, 2014.
resistance despite obesity,” *Diabetes*, vol. 64, no. 6, pp. 2116–2128, 2015.

[58] Y. H. Youm, K. Y. Nguyen, R. W. Grant et al., “The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease,” *Nature Medicine*, vol. 21, no. 3, pp. 263–269, 2015.

[59] M. M. Aleman, B. L. Walton, J. R. Byrnes, and A. S. Wolberg, “Fibrinogen and red blood cells in venous thrombosis,” *Thrombosis Research*, vol. 133, Supplement 1, pp. S38–S40, 2014.

[60] E. U. Nwose, “Whole blood viscosity assessment issues IV: prevalence in acute phase inflammation,” *North American Journal of Medical Sciences*, vol. 2, no. 8, pp. 353–358, 2010.

[61] P. Gyawali and R. S. Richards, “Association of altered hemorheology with oxidative stress and inflammation in metabolic syndrome,” *Redox Report*, vol. 20, no. 3, pp. 139–144, 2015.

[62] J. M. Rifkind, R. S. Ajmani, and J. Heim, “Impaired hemorheology in the aged associated with oxidative stress,” *Advances in Experimental Medicine and Biology*, vol. 428, pp. 7–13, 1997.